Psoriasis News and Research

Latest Psoriasis News and Research

New study links psoriasis severity to skin microbiome dysbiosis

A multi-omics analysis of host-microbe interactions in psoriasis.

28 Jun 2024

WEHI study reveals new methods in detecting necroptosis

Fully automated diagnostic techniques, including liquid handling robots, are poised to improve the lives of millions of people living with inflammatory diseases worldwide.

24 Jun 2024

Tips to help keep feet healthy during summer and prevent athlete’s foot

As the days heat up and we head into the Summer, many of us suddenly seem to remember that the appendages at the end of our legs need some love and care too.

22 Jun 2024

Study shows high burden of arthritis symptoms in patients people with psoriasis

Early results of an international study examining the risk of arthritis for people with psoriasis have shown a high burden of joint symptoms in 712 patients – 25% of the total studied so far.

22 Jun 2024

New research sheds light on IL-23's role in chronic inflammatory bowel diseases

Scientists at Weill Cornell Medicine discovered a previously unknown link between two key pathways that regulate the immune system in mammals-;a finding that impacts our understanding of chronic inflammatory bowel diseases (IBD).

12 Jun 2024

Microneedle patch holds promise for promoting hair regrowth caused by alopecia areata

Alopecia areata (AA) is an autoimmune disease characterized by hair loss, which occurs when T cells of the immune system mistakenly attack hair follicles.

8 Jun 2024

Genetic discovery reveals key to inflammatory diseases

Researchers discovered that a specific haplotype on chromosome 21 is linked to five inflammatory diseases, offering insights into potential new treatments.

7 Jun 2024

Innovative microneedle patch shows promise in treating alopecia areata

Alopecia areata (AA) is an autoimmune disease characterized by hair loss, which occurs when T cells of the immune system mistakenly attack hair follicles.

6 Jun 2024

Coupling bacteria-laden hydrogel and electronics for adaptive treatment of skin inflammation

Coupling skin bacteria-laden hydrogel and electronics, researchers have introduced the ABLE platform, a bioelectronics system that can deliver management and adaptive treatment of skin inflammation.

30 May 2024

New genetic discoveries offer hope for targeted lupus therapies

Lupus is a lifelong, often painful and occasionally lethal autoimmune disease. Few treatments exist today beyond powerful steroids to knock down a patient's immune system -; a therapy that has its own serious risks.

23 May 2024

Low stress resilience in youth linked to higher psoriasis risk later

Young adults who find it harder to cope with stress are more likely to develop psoriasis later in life. Low stress resilience when enlisting for military service involves a 31% higher risk of developing psoriasis compared to high stress resilience.

21 May 2024

Study uncovers key biological pathways driving psoriasis inflammation

A certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds.

20 May 2024

Study finds 41% of people with long-term itchiness have fatigue

41% of people with long-term itchiness have fatigue, likely due to persistent sleep disruption, according to new research published in the British Journal of Dermatology. In comparison, only 22% of the control group had fatigue.

15 May 2024

Researchers discover potential new treatment for alopecia areata

Researchers at MIT, Brigham and Women's Hospital, and Harvard Medical School have developed a potential new treatment for alopecia areata, an autoimmune disorder that causes hair loss and affects people of all ages, including children.

9 May 2024

Janssen-Cilag seeks European approval for guselkumab in ulcerative colitis and Crohn’s disease treatment

Janssen-Cilag International NV, a Johnson & Johnson company, today announced it has submitted applications to the European Medicines Agency (EMA) seeking to expand the Marketing Authorization Application for TREMFYA® (guselkumab) to include the treatment of adult patients with moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease.

6 May 2024